Definitive Contract 75A50124C00038
- Not listed
- The Office of the Assistant Secretary for Preparedness and Response awarded a $20 million definitive contract to Prenosis, Inc. on September 30, 2025, for host-based diagnostics and expansion of the Immunix platform for precision medicine in severe acute respiratory infections and ARDS. Place of performance is Chicago, IL. The contract runs through August 1, 2029, under firm fixed-price terms with no set-aside applied. Prenosis, Inc. is a small disadvantaged business that develops AI-enabled...
- The U.S. Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response awarded a definitive contract valued at approximately $28 million to Inflammatix, Inc. for the development of a comprehensive host-response diagnostic solution addressing infectious disease testing in both outpatient and inpatient settings. The contract, awarded September 25, 2019, with an ultimate completion date of May 7, 2027, supports Inflammatix's work in creating rapid...
- <p>The U.S. Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response, awarded a Firm Fixed Price contract to Proactive Diagnostics Inc., a small disadvantaged business, for Research and Development of the Q-Sense platform, an enabling technology for multiplexed home testing. The contract has a ceiling value of $720,580.39 and a period of performance ending on April 14, 2024. There is no set-aside designation for this award.</p>
- This is a $749,000.00 firm fixed price definitive contract awarded by the Office of the Assistant Secretary for Preparedness and Response, a civilian federal agency, to In Diagnostics, Inc. to develop endpoint and kinetic measurement capabilities on a low-cost, disposable spectrophotometer platform. The contract does not have a set-aside designation and is scheduled for completion by June 30, 2025. The awardee, In Diagnostics, Inc., is a for-profit organization located in Carlsbad, California.
- This is a definitive contract awarded by the Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response to Inflammatix, Inc., a self-certified small disadvantaged business. The contract is for the development of the HOSTDX-Sepsis diagnostic test, a rapid point-of-care test that analyzes the host immune response to detect and classify sepsis. The contract has a firm fixed price of $510,000.00 and a completion date of November 30, 2021....
- The Office of the Assistant Secretary for Preparedness and Response (ASPR) awarded a $727,799.32 firm fixed-price definitive contract to Memed Diagnostics LTD on September 22, 2023, to support research and development efforts demonstrating the clinical utility of MEMED BV, a rapid host-based diagnostic (HBD) platform designed to distinguish bacterial from viral infections. The contract extends through October 31, 2026, and will be performed in the Isle of Man. This work aligns with ASPR's...
- On November 29, 2021, the Office of the Assistant Secretary for Preparedness and Response (ASPR) awarded a $38.0 million firm fixed-price definitive contract to Monogram Biosciences, Inc. for the development and delivery of a high-throughput SARS-CoV-2 neutralizing antibody immunoassay capable of qualifying variants and testing human serum samples. The contract, which extends through September 30, 2029, is being performed at Monogram's laboratory facility in South San Francisco, California. As a...
- The U.S. Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response awarded a $749,999.00 Firm Fixed Price contract to 3EO Health Inc.'s Genpass division to develop a SARS-CoV-2 molecular diagnostic assay that meets the performance and characteristic requirements for Emergency Use Authorization (EUA). This is a definitive contract with no set-aside designation, and the period of performance extends through December 31, 2023. 3EO Health Inc. is a...
- This federal contract award, valued at $749,549.00, was made by the Office of the Assistant Secretary for Preparedness and Response (ASPR) to Immunexpress Inc., a for-profit foreign-owned company. The contract is for the "ASSESSMENT & TRIAGE OF PATIENTS WITH ESCALATING SIGNS OF COVID-19 DISEASE USING A HOST RESPONSE TEST FOR SEPSIS" and is a definitive, firm-fixed-price contract with a period of performance ending on June 10, 2023. The contract award originated from a Broad...
- This is a Firm Fixed Price contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the U.S. Department of Health and Human Services, to Godx Inc., a minority-owned small business. The $1,596,552.00 contract is for the development of a rapid, low-cost, point-of-care diagnostic test to detect enteric pathogens and antibiotic resistance. The goal is to create a diagnostic tool that can identify cholera, salmonella, shigella, and other...
The Office of the Assistant Secretary for Preparedness and Response awarded a $749.7K firm fixed-price contract to Gnomx Corp. (UEI: FJ8GSMZJ6EX1) on September 9, 2024, for development and validation of a host-based diagnostic assay under the GNOMX program's Area of Interest No. 23. The primary objective is to validate a host-based diagnostic capable of generating an immune dysregulation score compatible with point-of-care devices suitable for community setting deployment. The contract is structured as a definitive contract with no set-aside designation and carries an ultimate completion date of October 30, 2026, with performance to be conducted in New York, NY. The host-based assay is designed to predict the risk of post-discharge deterioration and readmission, supporting the Assistant Secretary for Preparedness and Response's broader mission of strengthening public health emergency preparedness and response capabilities. This development effort aligns with the department's focus on leveraging diagnostic innovations to improve patient outcomes and healthcare delivery in resource-constrained environments, enabling earlier identification of at-risk patients through accessible point-of-care testing platforms.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| P00004 | Supplemental Agreement for work within scope | $0 | 11/19/25 | |
| P00003 | Other Administrative Action | $0 | 8/13/25 | |
| P00002 | Other Administrative Action | $0 | 5/13/25 | |
| P00001 | Other Administrative Action | $0 | 10/17/24 | |
| Not listed | Not listed | $749.7k | 9/4/24 |